Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Last trade$6.86
Day change-$0.29 (-4.06%)
Day range$6.74 – $7.18
Volume62,909
Market cap$28M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$28.1M
Price / earnings
—
Price / book
-4.54×
Price / sales
0.55×
EV / sales
1.48×
EV / EBITDA
-1.62×
Profitability
Earnings per share
-$19.86
Return on assets
-60.59%
Return on equity
1,261.7%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-10.55×
Current ratio
1.78×
Quick ratio
1.1×
Cash ratio
0.56×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$32.56M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PTHS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Revenue
$15.4M
$15.6M
$10.91M
$9.39M
$7.41M
Cost of revenue
$1.66M
$3.61M
$1.67M
$1.67M
$2.32M
Gross profit
$13.73M
$11.99M
$9.23M
$7.72M
$5.09M
Selling, general and administrative
$18.85M
$27.67M
$21.1M
$18.47M
$18.38M
Research and development
$1.02M
$600K
$186K
$374K
$145K
Total operating expenses
$23.43M
$29.32M
$22.32M
$19.72M
$20.45M
Operating income
-$9.69M
-$17.32M
-$13.09M
-$12M
-$15.36M
Interest expense
-$2.27M
-$2.39M
-$2.35M
-$1.31M
-$1.35M
Income before taxes
-$7.9M
-$23.42M
-$25.07M
-$28.59M
-$16.7M
Income taxes
$0
$0
$0
-$6.92M
-$465K
Net income
-$7.9M
-$23.42M
-$25.07M
-$21.66M
-$16.24M
Net income attributable to common shareholders
-$7.9M
-$23.42M
-$25.07M
-$21.66M
-$16.24M
EBITDA
-$8.36M
-$16M
-$11.59M
-$10.79M
-$14.29M
Basic earnings per share
-$2.04
-$6.62
-$7.57
-$6.78
-$5.30
Diluted earnings per share
-$2.04
-$6.62
-$7.57
-$6.78
-$5.30
Recent news
Company coverage with links to the original publishers.
Pelthos Therapeutics reported a Q3 loss of $3.09 per share, missing consensus estimates of $2.83 loss, and posted revenues of $15.4 million, falling 15.34% short of expectations. Despite the miss, the company showed improvement from a year-ago loss of $5.3 per share. The stock has declined 69.7% year-to-date while the S&P 500 gained 11.3%. Zacks assigned the stock a Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
Pelthos Therapeutics reported strong Q3 2026 results with Zelsuvmi net product revenue reaching $15.2 million, up 114% year-over-year. The company announced a definitive merger agreement with Castle Creek Biosciences to create a diversified biotechnology company focused on dermatological and pediatric diseases, combining Pelthos' three FDA-approved products with Castle Creek's late-stage gene therapy candidate D-Fi for dystrophic epidermolysis bullosa.
Alvotech reported a quarterly loss of $0.03 per share, significantly worse than the consensus estimate of $0.01 loss, representing a -200% earnings surprise. Revenue of $111.56 million also missed estimates by 18.62%. The stock has underperformed the S&P 500 by 14.8% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.
Myriad Genetics (MYGN) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.17 loss, representing a 35.29% earnings surprise. Revenue of $202.7 million exceeded estimates by 7.48%, though down slightly year-over-year. The stock has underperformed the S&P 500 by 12.4% this year. Despite mixed performance, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends, with the Medical - Biomedical and Genetics industry ranking in the top 45% of sectors.
Pelthos Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026. The meeting date represents a change of more than 30 days from the 2025 Annual Meeting anniversary, with stockholder proposals due by August 3, 2026. The company is a commercial-stage biopharmaceutical firm focused on cutaneous infectious disease products.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.